OREANDA-NEWS. OJSC "VEROPHARM" [RTS:VRPH, MICEX:VFRM] announces its audited financial results of the year 2013 in accordance with the International Financial Reporting Standards (IFRS).

SALES

Sales in 2013 amounted to RUR 5,269 mln. The share of product segments in OJSC “Veropharm” sales is as follows:

Group of pharmaceutical products

Rx drugs sales amounted to RUR 3,725 mln. The Rx drugs sales made 70.7% of total sales of the Company against 66.8% in 2012;

OTC drugs sales amounted to RUR 794 mln. The OTC drugs sales made 15.1% of total sales of the Company against 14.4% in 2012;

Traditional drugs sales amounted to RUR 15 mln. The traditional drugs sales made 0.3% of total sales of the Company against 0.4% in 2012;

Group of non-pharmaceutical products

Non-pharmaceutical products sales made RUR 735 mln, which corresponds to 14.0% of total sales of the Company.

Under the Federal Rembursement Program (FRP) Veropharm's sales amounted to RUR 33.8 mln according to the results of 2013, which corresponds to 0.6% of the Company's total sales.

The Russian Federation is the main market and ensures 94.9% of the Company's sales. During 2013 the Company has exported 5.1% of its products.

PROFIT

In 2013 the gross profit of OJSC “Veropharm” amounted to RUR 3,132 mln. The gross profit ratio in 2013 made 59.4%. The gross profit ratio of the segments of OJSC “Veropharm” is as stated:

Group of pharmaceutical products

In relation to Rx drugs it made 58.4% in 2013 against 50.7% in 2012;

In relation to OTC drugs it made 66.2% in 2013 against 71.0% in 2012;

In relation to traditional products it made 46.3% in 2013 against 52.9% in 2012.

Group of non-pharmaceutical products

In relation to non-pharmaceutical products it made 57.6% in 2013 against 67.0% in 2012.

In 2013 EBITDA amounted to RUR 1,165 mln. EBITDA margin made 22.1%.

Operating profit in 2013 made RUR 1,038 mln. Operating profit margin made 19.7% in 2013.

Net profit for the reporting period amounted to RUR 612 mln. Net profit margin made 11.6%.

FACILITIES INVESTMENTS

In 2013 the amount of investments assigned for modernization and equipment of the main production facilities of the Company made RUR 2,894 mln.

DEBT

As at December 31, 2013 the debt of OJSC “Veropharm” amounted to RUR 2,667 mln, which makes no more than 30% of the Company's net assets value.